Although not investigated in experimental PAH, integrin inhibitors and antibody-mediated stabilization of latent TGF-β display efficacy in models of fibrosis or cancer (161–164), providing preclinical support for such approaches generally. Here, TGFB1 is linked to pulmonary arterial hypertension.